HES1 and medullary thyroid gland carcinoma: The BRAFV600E MTC cell line is prone to resistance to NOTCH pathway inhibitors mainly because the BRAFV600E mutation may bypass the NOTCH pathway and significantly enhance its downstream targets in TC, Hes family bHLH transcription factor 1 (HES-1) and HEY-1, thereby promoting tumorigenesis [93].